R

Antech introduces veterinary medicine's most advanced parasite screening test

Retrieved on: 
Monday, January 17, 2022 - 11:30am

Antech's investment in molecular technology, including 10 testing locations across North America, supports affordable next-day results, making advanced molecular parasite screening practical for routine wellness exams.

Key Points: 
  • Antech's investment in molecular technology, including 10 testing locations across North America, supports affordable next-day results, making advanced molecular parasite screening practical for routine wellness exams.
  • However, today's parasitic infection challenges have outpaced the capabilities of existing screening tests, the most common being the 100-year-old Ova and Parasite (O&P) diagnostic protocol.
  • KeyScreen GI Parasite PCRoffers several novel capabilities, supporting practice efficiency, rapid, cost-effective detection of more disease and a new, higher standard of care for parasite screening.
  • Today, Antech is driving the future of pet health as part of Mars Veterinary Health, a family-owned enterprise focused on veterinary care.

Insights on the Cobalt Global Market to 2027 - Featuring Carter Alloys, Coal India and Glencore Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 10:18am

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Key Points: 
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cobalt Market?
  • What is the market share of the leading vendors in the Global Cobalt Market?
  • What modes and strategic moves are considered suitable for entering the Global Cobalt Market?

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 10:08am

HANGZHOU and SHAOXING, China, Jan. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Global Portable Lithium Power Station Market Research Report (2021 to 2027) - by Type, Capacity, Sales channel, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:55am

What is the market size and forecast of the Global Portable Lithium Power Station Market?

Key Points: 
  • What is the market size and forecast of the Global Portable Lithium Power Station Market?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Portable Lithium Power Station Market?
  • What is the market share of the leading vendors in the Global Portable Lithium Power Station Market?
  • What modes and strategic moves are considered suitable for entering the Global Portable Lithium Power Station Market?

Worldwide Welding Materials Industry to 2027 - Introduction of Smart Materials in Welding Industry Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:52am

What are the inhibiting factors and impact of COVID-19 shaping the Global Welding Materials Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Welding Materials Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Welding Materials Market?
  • What is the competitive strategic window for opportunities in the Global Welding Materials Market?
  • What modes and strategic moves are considered suitable for entering the Global Welding Materials Market?

Insights on the Oral Rehydration Salts Global Market to 2027 - Featuring Cian Healthcare, Doyen Healthcare and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:49am

What are the inhibiting factors and impact of COVID-19 shaping the Global Oral Rehydration Salts Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Oral Rehydration Salts Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oral Rehydration Salts Market?
  • What is the market share of the leading vendors in the Global Oral Rehydration Salts Market?
  • What modes and strategic moves are considered suitable for entering the Global Oral Rehydration Salts Market?

Worldwide Refractive Surgery Devices Global Market to 2027 - Upsurging Adaptations Towards the Painless Surgeries Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:47am

What are the inhibiting factors and impact of COVID-19 shaping the Global Refractive Surgery Devices Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Refractive Surgery Devices Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Refractive Surgery Devices Market?
  • What is the market share of the leading vendors in the Global Refractive Surgery Devices Market?
  • What modes and strategic moves are considered suitable for entering the Global Refractive Surgery Devices Market?

Global Dental Fluoride Treatment Market Research Report (2021 to 2027) - by Product, Type, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:43am

What are the inhibiting factors and impact of COVID-19 shaping the Global Dental Fluoride Treatment Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Dental Fluoride Treatment Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Dental Fluoride Treatment Market?
  • What is the market share of the leading vendors in the Global Dental Fluoride Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Dental Fluoride Treatment Market?

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 9:53am

Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

EcoFlow Launches the DELTA Pro, its Pioneering Portable Power Station, in Europe

Retrieved on: 
Monday, January 17, 2022 - 7:00am

PARDUBICE, Czech Republic, Jan. 17, 2022 /PRNewswire/ -- EcoFlow, a portable power and renewable energy solutions company, has launched the industry-leading DELTA Pro portable home battery in Europe. Originally a Kickstarter campaign, it smashed records to become the most-funded tech project at the time and still ranks sixth among all projects to date.

Key Points: 
  • In September 2021, EcoFlow launched the DELTA Max and the DELTA mini in Europe, both of which are designed to offer backup power for shorter blackout periods.
  • "DELTA Pro's highly successful Kickstarter campaign overwhelmingly demonstrates the consumer desire for portable clean energy power and storage solutions," said Thomas Chan, R&D Director at EcoFlow.
  • "Reliable access to power is front-of-mind for consumers, as rising cases of extreme weather and power outages emphasize the need for greater preparation and sustainable power sources.
  • Since its founding in 2017, EcoFlow has provided peace-of-mind power to customers in over 85 markets through its DELTA and RIVER product lines of portable power stations and eco-friendly accessories.